Cash flow Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Delayed Nyse Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
9.130 ^USD	+2.24%		+2.70%	+3.51%

Jan. 15	Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment	MT
Jan. 15	Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder	CI

b1a2da54d3420e5e2733879.tnJC-avwGQ5CnmXIGJ0Gb0vgRCrrz62wJwmfAz-FzTo.7Chxz--mdF4r1w-YesVcCznRcG2pq5vUSFbdRknauQvlPXaUwZVuOXTWNA

Published financial data: CYBIN INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2020	2021	2022	2023	2024
Revenues	-	864K	-	-	-
Total Revenues	-	864K	-	-	-
Cost of Goods Sold, Total	-	1.18M	-	-	-
Gross Profit	-	-311K	-	-	-
Selling General & Admin Expenses, Total	1.48M	15.87M	28.22M	21.34M	32.59M
Stock-Based Compensation (IS)	155K	11.55M	18.03M	4.69M	13.89M
R&D Expenses	321K	3.3M	17.59M	25.49M	32.36M
Other Operating Expenses, Total	1.95M	30.72M	63.84M	51.52M	78.84M
Operating Income	-1.95M	-31.04M	-63.84M	-51.52M	-78.84M
Interest Expense, Total	-	-10K	-	-	-
Interest And Investment Income	-	60K	241K	603K	619K
Net Interest Expenses	-	50K	241K	603K	619K
Currency Exchange Gains (Loss)	9.91K	-460K	-309K	4.03M	137K
EBT, Excl. Unusual Items	-1.94M	-31.44M	-63.91M	-46.89M	-78.08M
Gain (Loss) On Sale Of Investments	-	-63K	-29K	-260K	-
Other Unusual Items	-	-712K	-3.7M	-342K	-
EBT, Incl. Unusual Items	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Earnings From Continuing Operations	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Net Income to Company	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Net Income - (IS)	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Net Income to Common Incl Extra Items	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Net Income to Common Excl. Extra Items	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Per Share Items
Net EPS - Basic	-9.86	-12.24	-15.36	-9.73	-9.41
Basic EPS - Continuing Operations	-9.86	-12.24	-15.36	-9.73	-9.41
Basic Weighted Average Shares Outstanding	197K	2.63M	4.4M	4.88M	8.3M
Net EPS - Diluted	-9.86	-12.24	-15.36	-9.88	-9.5
Diluted EPS - Continuing Operations	-9.86	-12.24	-15.36	-9.88	-9.5
Diluted Weighted Average Shares Outstanding	197K	2.63M	4.4M	4.88M	8.3M
Normalized Basic EPS	-6.16	-7.47	-9.07	-6	-5.88
Normalized Diluted EPS	-6.16	-7.47	-9.07	-6	-5.88
Supplemental Items
EBITDA	-	-30.99M	-63.67M	-51.28M	-78.58M
EBITA	-1.95M	-31.04M	-63.84M	-51.5M	-78.8M
EBIT	-1.95M	-31.04M	-63.84M	-51.52M	-78.84M
Normalized Net Income	-1.21M	-19.65M	-39.94M	-29.3M	-48.8M
Interest on Long-Term Debt	-	-	-	-	8K
Supplemental Operating Expense Items
Advertising Expense	48.78K	-	-	-	-
Marketing Expenses	-	4.94M	3.69M	1.54M	2.79M
Selling and Marketing Expenses	117K	4.94M	3.69M	1.54M	2.79M
General and Administrative Expenses	1.25M	10.92M	24.53M	19.81M	29.8M
Research And Development Expense From Footnotes	321K	3.3M	17.59M	25.49M	32.36M
Stock-Based Comp., Other (Total)	155K	11.58M	18.03M	4.69M	13.89M
Total Stock-Based Compensation	155K	11.58M	18.03M	4.69M	13.89M

Fiscal Period: March	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	1.55M	64.03M	53.64M	16.63M	209M
Total Cash And Short Term Investments	1.55M	64.03M	53.64M	16.63M	209M
Accounts Receivable, Total	-	1.33M	-	-	-
Other Receivables	74.02K	-	2.1M	3.05M	4.48M
Total Receivables	74.02K	1.33M	2.1M	3.05M	4.48M
Prepaid Expenses	20.38K	1.13M	1.27M	1.73M	2.89M
Other Current Assets, Total	-	-	1.34M	1.77M	2.18M
Total Current Assets	1.64M	66.48M	58.36M	23.18M	219M
Gross Property Plant And Equipment	-	611K	713K	903K	1.35M
Accumulated Depreciation	-	-54K	-222K	-453K	-807K
Net Property Plant And Equipment	-	557K	491K	450K	547K
Long-term Investments	70.94K	-	242K	-	-
Goodwill	-	23.37M	22.89M	24.79M	47.48M
Other Intangibles, Total	-	1.7M	2.08M	5.47M	35.46M
Total Assets	1.71M	92.11M	84.06M	53.9M	302M
Liabilities
Accounts Payable, Total	147K	2.79M	4.23M	5.66M	9.8M
Accrued Expenses, Total	116K	-	1.04M	-	-
Current Portion of Leases	-	-	-	-	291K
Other Current Liabilities	-	2.11M	2.65M	-	-
Total Current Liabilities	263K	4.9M	7.91M	5.66M	10.1M
Other Non Current Liabilities	-	1.09M	-	-	-
Total Liabilities	263K	5.99M	7.91M	5.66M	10.1M
Common Stock, Total	2.19M	101M	141M	158M	444M
Additional Paid In Capital	-	124K	525K	2.1M	11.75M
Retained Earnings	-810K	-33.03M	-101M	-148M	-226M
Comprehensive Income and Other	64.48K	18.35M	34.84M	36.12M	62.53M
Total Common Equity	1.45M	86.12M	76.16M	48.23M	292M
Total Equity	1.45M	86.12M	76.16M	48.23M	292M
Total Liabilities And Equity	1.71M	92.11M	84.06M	53.9M	302M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	56.5M	3.91M	4.64M	5.62M	20M
ECS Total Common Shares Outstanding	56.5M	3.89M	4.61M	5.28M	20M
Book Value / Share	0.03	22.13	16.52	9.13	14.59
Tangible Book Value	1.45M	61.05M	51.18M	17.97M	209M
Tangible Book Value Per Share	0.03	15.69	11.1	3.4	10.45
Total Debt	0	0	0	0	291K
Net Debt	-1.55M	-64.03M	-53.64M	-16.63M	-209M
Account Code - Inventory Valuation	3	5	5	5	5
Machinery, Total	-	611K	713K	903K	930K
Full Time Employees	-	38	50	50	50

Fiscal Period: March	2020	2021	2022	2023	2024
Net Income	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M
Depreciation & Amortization - CF	-	49K	168K	214K	363K
Amortization of Goodwill and Intangible Assets - (CF)	-	-	-	19K	37K
Depreciation & Amortization, Total	-	49K	168K	233K	400K
Amortization of Deferred Charges, Total - (CF)	-	-	-	18K	24K
(Gain) Loss on Sale of Investments - (CF)	-	63K	29K	260K	-
Asset Writedown & Restructuring Costs	-	-	-	-	18K
Stock-Based Compensation (CF)	155K	11.55M	18.03M	4.69M	13.89M
Other Operating Activities, Total	-	2.79M	3.98M	-3.7M	-129K
Change In Accounts Receivable	-178K	-1.48M	-773K	-948K	-1.09M
Change In Inventories	-	-511K	-	-	-
Change In Accounts Payable	630K	1.8M	2.47M	401K	-2.54M
Change in Other Net Operating Assets	-48.92K	-1.07M	-1.48M	-890K	-1.39M
Cash from Operations	-1.39M	-19.03M	-45.21M	-47.43M	-68.91M
Capital Expenditure	-	-135K	-105K	-142K	-21K
Cash Acquisitions	-	-958K	-	-	7.63M
Sale (Purchase) of Intangible assets	-	-96K	-415K	-3.17M	-689K
Investment in Marketable and Equity Securities, Total	-170K	-	-250K	-	-
Cash from Investing	-170K	-1.19M	-770K	-3.31M	6.92M
Long-Term Debt Repaid, Total	-	-	-	-	-149K
Total Debt Repaid	-	-	-	-	-149K
Issuance of Common Stock	5.41M	76.82M	38.77M	14.51M	271M
Other Financing Activities, Total	-149K	5.9M	-2.99M	-950K	-16.68M
Cash from Financing	5.26M	82.72M	35.78M	13.56M	255M
Foreign Exchange Rate Adjustments	-	-28K	-185K	168K	-162K
Net Change in Cash	3.71M	62.48M	-10.38M	-37.01M	192M
Supplemental Items
Levered Free Cash Flow	-	-5.73M	-21.47M	-34.65M	-34.52M
Unlevered Free Cash Flow	-	-5.73M	-21.47M	-34.65M	-34.52M
Change In Net Working Capital	-	-2.27M	-752K	4.08M	-1.15M
Net Debt Issued / Repaid	-	-	-	-	-149K

Fiscal Period: March	2020	2021	2022	2023	2024
Profitability
Return on Assets	-	-41.35	-45.29	-46.68	-27.69
Return on Total Capital	-	-44.3	-49.17	-51.77	-28.95
Return On Equity %	-	-73.59	-83.35	-76.36	-45.91
Return on Common Equity	-	-73.59	-83.35	-76.36	-45.91
Margin Analysis
Gross Profit Margin %	-	-36	-	-	-
SG&A Margin	-	1.84K	-	-	-
EBITDA Margin %	-	-3.59K	-	-	-
EBITA Margin %	-	-3.59K	-	-	-
EBIT Margin %	-	-3.59K	-	-	-
Income From Continuing Operations Margin %	-	-3.73K	-	-	-
Net Income Margin %	-	-3.73K	-	-	-
Net Avail. For Common Margin %	-	-3.73K	-	-	-
Normalized Net Income Margin	-	-2.27K	-	-	-
Levered Free Cash Flow Margin	-	-663.67	-	-	-
Unlevered Free Cash Flow Margin	-	-662.95	-	-	-
Asset Turnover
Asset Turnover	-	0.02	-	-	-
Receivables Turnover (Average Receivables)	-	1.23	-	-	-
Short Term Liquidity
Current Ratio	6.24	13.57	7.38	4.09	21.65
Quick Ratio	6.17	13.34	7.05	3.48	21.14
Operating Cash Flow to Current Liabilities	-5.28	-3.88	-5.72	-8.38	-6.83
Days Sales Outstanding (Average Receivables)	-	296.35	-	-	-
Average Days Payable Outstanding	-	474.66	-	-	-
Long Term Solvency
Total Debt/Equity	-	-	-	-	0.1
Total Debt / Total Capital	-	-	-	-	0.1
Total Liabilities / Total Assets	15.35	6.51	9.41	10.51	3.34
EBIT / Interest Expense	-	-3.1K	-	-	-
EBITDA / Interest Expense	-	-3.1K	-	-	-
(EBITDA - Capex) / Interest Expense	-	-3.11K	-	-	-
Total Debt / EBITDA	-	-	-	-	-0
Net Debt / EBITDA	-	2.07	0.84	0.32	2.66
Total Debt / (EBITDA - Capex)	-	-	-	-	-0
Net Debt / (EBITDA - Capex)	-	2.06	0.84	0.32	2.66
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	-	-	105.48	-19.45	53.21
EBITA, 1 Yr. Growth %	-	1.49K	105.7	-19.33	53.01
EBIT, 1 Yr. Growth %	-	1.49K	105.7	-19.3	53.03
Earnings From Cont. Operations, 1 Yr. Growth %	-	1.56K	109.9	-29.78	64.41
Net Income, 1 Yr. Growth %	-	1.56K	109.9	-29.78	64.41
Normalized Net Income, 1 Yr. Growth %	-	1.52K	103.23	-26.63	66.52
Diluted EPS Before Extra, 1 Yr. Growth %	-	571.16	25.49	-35.69	-3.85
Accounts Receivable, 1 Yr. Growth %	-	1.7K	-	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-	-	-11.85	-8.35	21.56
Total Assets, 1 Yr. Growth %	-	5.28K	-8.74	-35.88	460.37
Tangible Book Value, 1 Yr. Growth %	-	4.12K	-16.16	-64.88	1.06K
Common Equity, 1 Yr. Growth %	-	5.85K	-11.57	-36.66	505.23
Cash From Operations, 1 Yr. Growth %	-	1.27K	137.59	4.92	45.28
Capital Expenditures, 1 Yr. Growth %	-	-	-22.22	35.24	-85.21
Levered Free Cash Flow, 1 Yr. Growth %	-	-	274.4	61.41	-0.38
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	274.81	61.41	-0.38
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	-	-	28.65	11.09
EBITA, 2 Yr. CAGR %	-	-	471.64	28.82	11.1
EBIT, 2 Yr. CAGR %	-	-	471.64	28.84	11.13
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	489.83	21.41	7.45
Net Income, 2 Yr. CAGR %	-	-	489.83	21.41	7.45
Normalized Net Income, 2 Yr. CAGR %	-	-	473.35	22.11	10.53
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	190.21	-10.16	-21.36
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-	-10.12	5.55
Total Assets, 2 Yr. CAGR %	-	-	600.93	-23.51	89.55
Tangible Book Value, 2 Yr. CAGR %	-	-	494.52	-45.74	102.07
Common Equity, 2 Yr. CAGR %	-	-	625.21	-25.16	95.79
Cash From Operations, 2 Yr. CAGR %	-	-	471.36	57.89	23.46
Capital Expenditures, 2 Yr. CAGR %	-	-	-	2.56	-55.28
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-	145.83	26.81
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-	145.97	26.81
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	-	-	36.37
EBITA, 3 Yr. CAGR %	-	-	-	197.61	36.42
EBIT, 3 Yr. CAGR %	-	-	-	197.65	36.44
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	-	190.16	34.32
Net Income, 3 Yr. CAGR %	-	-	-	190.16	34.32
Normalized Net Income, 3 Yr. CAGR %	-	-	-	188.93	35.41
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	75.62	-8.11
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-	-	-0.6
Total Assets, 3 Yr. CAGR %	-	-	-	215.82	48.56
Tangible Book Value, 3 Yr. CAGR %	-	-	-	131.53	50.71
Common Equity, 3 Yr. CAGR %	-	-	-	221.76	50.22
Cash From Operations, 3 Yr. CAGR %	-	-	-	224.76	53.57
Capital Expenditures, 3 Yr. CAGR %	-	-	-	-	-46.22
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	-	81.92
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	-	81.99